CNTB Connect Biopharma Holdings Limited Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
15:05
Sep 08
Sep 08
CNTB Phase 2 results due September
Author is watching CNTB because two Phase 2 trial results for rademikibart in asthma and COPD are expected in September, with 160 and 159 patients respectively. If results are strong, the company plans to meet with the FDA about moving toward Phase 3, which could bring significantly more attention to the stock. The company reported about $31.5 million in cash and investments, enough to fund operations for at least another year. The main risk is that everything now depends on the trial results.
HIGH
15:02
Sep 06
Sep 06
Research list of high-risk speculative biotechs
The speaker recommends researching a list of speculative small-cap biotech names, acknowledging high risk, without endorsing a directional trade.
LOW
14:23
Sep 06
Sep 06
CNTB watch, AI output only
AI-generated respiratory/biologic pick; author explicitly not recommending; watch only.
MED
About CNTB Analyst Coverage
Buzzberg tracks CNTB (Connect Biopharma Holdings Limited) across 3 sources. 0 bullish vs 0 bearish calls from 3 analysts. Sentiment: evenly split. 3 total trade ideas tracked. Past 7 days: 3 watch. Latest voices: u/UNCLEJASSY, sandeman52, aleabitoreddit.